Impact of Proportional Assisted Ventilation on Dyspnea and Asynchrony in Mechanically Ventilated Patients (DYS-PAV)

July 13, 2020 updated by: Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil

Rational. The mismatch between the activity of the respiratory muscles and the assistance delivered by the ventilator results in patient-ventilator disharmony, which is commonly observed in ICU patients and is associated with dyspnea and patient-ventilator asynchrony. Both dyspnea and asynchrony are in turn associated with a worse prognosis. Unlike conventional modes of mechanical ventilation, such as pressure support ventilation (PSV) that deliver a constant level of assistance regardless of the patient effort, Proportional Assisted Ventilation (PAV) adjusts the level of ventilator assistance to the activity of respiratory muscles. To date, data on the impact of PAV on dyspnea and patient ventilator asynchrony are scarce and most studies have been conducted in healthy subjects or in ICU patients who had no severe dyspnea nor severe asynchrony. To our knowledge, there are no data in patients with severe patient-ventilator dysharmony.

Study Aim. To evaluate the impact of PAV on dyspnea and patient-ventilator asynchrony in ICU mechanically ventilated patients in intensive care with severe patient-ventilator disharmony defined as either severe dyspnea or severe patient-ventilator asynchrony.

Patients and Methods. Will be included 24 ICU mechanically ventilated patient exhibiting severe patient-ventilator dysharmony with PSV. The intensity of dyspnea will be assessed by the VAS, the ICRDOSS and by the electromyogram of extradiaphragmatic inspiratory muscles and pre inspiratory potential collected from the electroencephalogram. The prevalence of patient-ventilator asynchrony will be quantified.

Expected results. It is anticipated that the switch from PSV to PAV will decrease the prevalence and severity of dyspnea and the prevalence of patient-ventilator asynchrony.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Rational As opposed to controlled mechanical ventilation, partial modes of assisted ventilation maintains a certain level spontaneous activity of respiratory muscles. As a consequence, assisted ventilation may contribute to prevents ventilator induced diaphragm dysfunction (1-3), improves gas exchanges (4), reduces the use of sedative agents, which can ultimately shorten weaning from mechanical ventilation (5).

The most widely used partial ventilatory assistance mode is pressure support ventilation (PSV) (6), in which a constant preset level of pressure assists each inspiration regardless of the patient's inspiratory effort. Mismatching between patient demand and level of assistance, which the investigators will term patient-ventilator dysharmony in the present project is therefore possible and can be potentially harmful. On the one hand, underassistance may induce respiratory discomfort and dyspnea (7), which is an immediate cause of suffering, generates anxiety and is a source of delayed neuropsychological sequelae such as dark respiratory recollections and post-traumatic stress disorders(8-12). One the other hand, overassistance may cause lung overdistension and volutrauma (13). Finally, both underassistance and overassistance may generate patient-ventilator asynchrony that is associated with poorer clinical outcomes (14). Of notice, underassistance is likely to be associated with an asynchrony named double-triggering while over assistance is more commonly associated with ineffective efforts(15).

Proportional modes of mechanical ventilation have been designed to overcome this weakness of (PSV). Indeed, as opposed to PSV that delivers a constant level of assistance regardless of the patient inspiratory effort, proportional modes of ventilation adjust the amount of assistance delivered with respect to the patient's efforts. Proportional Assisted Ventilation (PAV) is one of these modes and adjusts ventilator assistance to the activity of respiratory muscles estimated by an algorithm (16-23). Previous studies have shown the potential benefits of PAV to prevent the risk of overassistance(24) and in turn to reduce the prevalence of ineffective effort (25-28). In addition, PAV increases the variability of the breathing pattern (17, 20-23, 29-32). To date, data on the impact of PAV on dyspnea and patient ventilator asynchrony are scarce (24-28, 33). Most of these works have been conducted in healthy subjects or in ICU patients with no severe dyspnea nor severe asynchrony (24-28, 33). To our knowledge, there are no data in patients with severe patient-ventilator dysharmony.

Because PAV adjusts the level of assistance to the activity of respiratory muscles, a surrogate of the respiratory drive, it is licit to hypothesize that PAV should prevent severe patient-ventilator dysharmony, defined as either severe dyspnea or severe patient-ventilator asynchrony.

The objective of the present research proposal is to evaluate the impact of PAV on dyspnea and patient-ventilator asynchrony in ICU mechanically ventilated patients in intensive care with severe patient-ventilator disharmony defined as either severe dyspnea or severe patient-ventilator asynchrony.

The specific objectives are to compare in these patients the impact of a switch of the ventilator mode from PSV to PAV in terms of:

  1. The intensity of dyspnea quantified by a self-assessment visual analogic scale and by two electrophysiological tools such as the electromyogram of extradiaphragmatic inspiratory muscles and the pre inspiratory potentials on the electroencephalogram (see below, Patients and Methods).
  2. The prevalence of two major patient-ventilator asynchronies that are ineffective efforts and double triggering (see below, Patients and Methods).

Materials and methods used and statistical methods

This observational, single-centre prospective study will be performed in the Medical intensive care unit (ICU) of the Respiratory and ICU Division of Pitié-Salpêtrière hospital, Paris, France.

1. Population, sampling The inclusion of patients will be done after informing patients and obtaining their informed consent.

1.1 Inclusion criteria Patients will be included as soon as the meet the following criteria.

  • Intubation and mechanical ventilation for a respiratory cause with severe hypoxemia defined as a PaO2 to FiO2 ratio <300 recorded at least once during the present ICU stay.
  • PSV ventilation for > 6 hours.
  • Severe patient-ventilator disharmony
  • Decision of the physician in charge of the patient to switch mechanical ventilation from PSV mode to PAV.
  • Remaining duration of mechanical ventilation estimated ≥ 24 hours. 1.2 Exclusion criteria Exclusion criteria will be as follows.
  • Severe hypoxemia defined as a PaO2 to FiO2 ratio <150 mmHg.
  • Delirium according to the CAM-ICU (1)
  • Hemodynamic instability defined by the need for intravenous fluids or catecholamine during the previous 24 hours.

  • Age <18 years; pregnant woman. 1.3 sample size Our objective is to study a convenient sample of 24 patients. Given the recruitment unit, the duration of the study should be 6 months.

    2 Study design A first 10-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.

The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min (8). As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al.(8). This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 10-minutes stabilization period, a 10-minutes recording will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously.

During the whole procedure, the usual hemodynamic and respiratory variables - non-invasive blood pressure or invasive if any, pulse oximetry, respiratory rate, - will be monitored continuously.

4 Statistical analysis Statistical analysis will be conducted with the Prism 5.0 software (GraphPad Software, USA). The distribution followed by the analysed data will be evaluated by the normality test of Kolmogorov-Smirnov. Probability of Type I error p less than or equal to 0.05 will be considered statistically significant. To investigate the effects of ventilation mode, the descriptors of dyspnea, the amplitude of the EMG as well as the PPI will be compared using a Mann-Whitney test. The prevalence of main asynchronies will be compared with a

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Paris, France, 75013
        • Service de Pneumologie et Réanimation Médicale, Groupe Hospitalier Pitié Salpêtrière

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Patients will be included as soon as the meet the following criteria.

  • Intubation and mechanical ventilation for a respiratory cause with severe hypoxemia defined as a PaO2 to FiO2 ratio <300 recorded at least once during the present ICU stay.
  • PSV ventilation for > 6 hours.

  • Severe patient-ventilator disharmony defined by either

    • a dyspnea ≥ 4 on a visual analogic scale (VAS) from 0 to 10 with respiratory rate ≥ 24 /minute and a drawing of neck muscles,
    • or by an asynchrony index (IA) ≥ 10%, defined as = number of asynchrony events/total respiratory rate (ventilator cycles +wasted efforts) × 100

  • No improvement of disharmony despite an optimization of ventilator setting defined as follows.

    • No improvement of dyspnea or double triggering despite an increase of the level of pressure support that should not generate a tidal volume > 10 ml/kg
    • No improvement of ineffective efforts despite a decrease of the level of pressure support or generation of a dyspnea (defined as VAS>4) in response of the decrease of the level of pressure support.
  • Decision of the physician in charge of the patient to switch mechanical ventilation from PSV mode to PAV.
  • Remaining duration of mechanical ventilation estimated ≥ 24 hours.
  • Patient able to communicate (Richmond Agitation and Sedation Scale between -1 and +1).

Exclusion Criteria:

  • Exclusion criteria will be as follows.

    • Severe hypoxemia defined as a PaO2 to FiO2 ratio <150 mmHg.
    • Delirium according to the CAM-ICU (1)
    • Hemodynamic instability defined by the need for intravenous fluids or catecholamine during the previous 24 hours.
    • Age <18 years; pregnant woman.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ventilator settings, PAV

A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.

The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min.
Device: PAV, Puritan Bennett 980 ventilator
The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantification of dyspnea
Time Frame: in real time, during the procedure
Dyspnea will be quantified with with the ICU Respiratory Distress Operating Scale (IC-RDOS)
in real time, during the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Airway pressure
Time Frame: in real time, during the procedure
The airway pressure will be also measured at the Y-piece by a differential pressure transducer (Validyne, Northridge, USA).
in real time, during the procedure
Electromyography (EMG) of extra inspiratory diaphragmatic muscles
Time Frame: in real time, during the procedure
The amplitude of the EMG signal of extradiaphragmatics inspiratory muscles is proportional to the intensity of dyspnea. EMG will be collected by self-adhesive surface electrodes of the same type as those commonly used to collect the ECG signal in critically ill patients. A distance of 2 cm will separate the two electrodes. The position of the electrodes will depend on the recorded muscle.
in real time, during the procedure
Electroencephalogram (EEG) in search of a pre-inspiratory potential
Time Frame: in real time, during the procedure
The application of an inspiratory resistive load to healthy subjects results in the activation of the pre-motor cortex detected by EEG recording. This EEG activity is named pre-inspiratory potential (PIP).
in real time, during the procedure
Arterial blood gas
Time Frame: in real time, during the procedure
For patients with an arterial catheter, the measurement of blood gases using an arterial blood sample of a volume of less than 1ml be performed at the end of each condition.
in real time, during the procedure
Patient-ventilator asynchrony
Time Frame: in real time, during the procedure
Asynchrony will be detected by visual inspection of the recordings. The investigators will investigate patterns of two major asynchronies that are easily detected on pressure and flow recordings: ineffective triggering and double triggering. Ineffective triggering will be defined as an abrupt airway pressure drop (≥ 0.5 cmH2O) simultaneous to a flow decrease (in absolute value) and not followed by an assisted cycle during the expiratory period. Double-triggering will be defined as two cycles separated by a very short expiratory time, defined as less than one-half of the mean inspiratory time, the first cycle being patient-triggered.
in real time, during the procedure
Flow
Time Frame: in real time, during the procedure
Airway flow will be measured with a pneumotachograph (Hans Rudolph, Kansas City, USA) inserted between the Y-piece and the endotracheal tube and connected to a differential pressure sensor (Validyne, Northridge, USA).
in real time, during the procedure
Quantification of dyspnea
Time Frame: in real time, during the procedure
Dyspnea will be quantified with a dyspnea-VAS from 0 (no discomfort) to 10 (maximum breathing)
in real time, during the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 24, 2016

Primary Completion (Actual)

December 31, 2017

Study Completion (Actual)

December 31, 2017

Study Registration Dates

First Submitted

May 6, 2016

First Submitted That Met QC Criteria

June 13, 2016

First Posted (Estimate)

June 16, 2016

Study Record Updates

Last Update Posted (Actual)

July 14, 2020

Last Update Submitted That Met QC Criteria

July 13, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ADOREPS_1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyspnea

Clinical Trials on PAV, Puritan Bennett 980 ventilator

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe